← Leaderboards
Rob R Macgregor
University Of Pennsylvania
$4,980,820
Attributed
$4,980,820
Total exposure
24
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$4,980,820 · 24
By mechanism
M01$4,980,820 · 23
P01$0 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Pennsylvania
Same institution · by research overlap
- Gregory P. Bisson$13,346,066
- Harvey Rubin$4,989,296
- Andras Schaffer$703,252
- Phillip A. Scott$24,920,033
- Nicola Mario Zetola$3,276,980
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectClinical ResearchHuman Therapy EvaluationAids TherapyHiv InfectionsClinical Trial Phase IDrug Screening /EvaluationOpportunistic InfectionsMicroorganism Disease ChemotherapyMycobacterium AviumClinical TrialsPathologic ProcessPharmacokineticsAntiaids AgentVector VaccineAids VaccinesAidsVirus LoadLeukocyte CountHormone TherapyDosageCombination ChemotherapyEye Disorder ChemotherapyAzithromycin
Grant awards (91)
OBSERVATIONAL STUDY OF THE PHARMACOKINETICS OF EFAVIRENZ AND NEVIRAPINE$18,999
M01 · FY2005 · RR
IMPACT OF THERAPEUTIC DRUG MONITORING ON VIROLOGIC RESPONSE TO A SALVAGE REGIMEN$11,874
M01 · FY2005 · RR
AACTG: INCREASE IN CD4 CELLS ON ANTIRETROVIRAL THERAPY IN AIDS SUBJECTS$6,334
M01 · FY2005 · RR
TRIAL OF VALGANCICLOVIR PRE-EMPTIVE THERAPY FOR CYTOMEGALOVIRUS (CMV)$3,166
M01 · FY2005 · RR
SINGLE DOSE OF AUTOLOGOUS T CELLS TRANSDUCED WITH VRX496$791
M01 · FY2005 · RR
Increase in CD4 Cells on Antiretroviral Therapy in AIDS Subjects$18,634
M01 · FY2004 · RR
The Pharmacokinetic Eval of Dapsone in Subjects w/Chronic Renal Insufficiency$11,364
M01 · FY2004 · RR
REDUCED SERUM TESTOSTERONE LEVELS AND ABDOMINAL OBESITY$1,695
M01 · FY2004 · RR
GENEVAX HIV, CANDIDATE DNA VACCINE SAFETY, TOLERABILITY AND IMMUNOGENEITY$124,146
M01 · FY2002 · RR
ACTG 323--FLUCONAZOLE AS CHRONIC SUPPRESSIVE THERAPY VS EPISODIC THERAPY$124,146
M01 · FY2002 · RR
ACTG 368--INDINAVIR SULFATE, DMP266, &1592U89 IN HIV INFECTED SUBJECTS$124,146
M01 · FY2002 · RR
ACTG 393: SUBJECTS W/ DISSEMINATED MYCOBACTERIUM COMPLEX$124,146
M01 · FY2002 · RR
ACTG 888: IMPACT OF DISCONTINUING PRIMARY PCP PROPHYLAXIS IN CD4 COUNTS$124,146
M01 · FY2002 · RR
ACTG 309: PHARMACOKINETICS OF ANTITUBERCULOSIS AGENTS IN HIV INFECTED PTS WITH TB$124,146
M01 · FY2002 · RR
ACTG 329: NANDROLONE DECANOATE IN WOMEN WITH HIV WT LOS$124,146
M01 · FY2002 · RR
DNA PLASMID VACCINE IN ASYMPTOMATIC HIV$124,146
M01 · FY2002 · RR
ACTG 341: MAC DISEASE IN ADVANCED HIV-1 INFECTION--HAART$124,146
M01 · FY2002 · RR
RS-79070 (VALGANCICLOVIR) VS IV GANCICLOVIR AS INDUCTION THERAPY FOR CMV RETINITI$124,146
M01 · FY2002 · RR
ACTG 362--EFFICACY OF AZITHROMYCIN PROPHYLAXIS FOR PREVENTION OF MAC DISEASES$124,146
M01 · FY2002 · RR
HUMAN CLINICAL STUDIES$0
P01 · FY2002 · AI
ACTG 362--EFFICACY OF AZITHROMYCIN PROPHYLAXIS FOR PREVENTION OF MAC DISEASES$124,146
M01 · FY2001 · RR
GENEVAX HIV, CANDIDATE DNA VACCINE SAFETY, TOLERABILITY AND IMMUNOGENEITY$124,146
M01 · FY2001 · RR
ACTG 393: SUBJECTS W/ DISSEMINATED MYCOBACTERIUM COMPLEX$124,146
M01 · FY2001 · RR
ACTG 888: IMPACT OF DISCONTINUING PRIMARY PCP PROPHYLAXIS IN CD4 COUNTS$124,146
M01 · FY2001 · RR
ACTG 309: PHARMACOKINETICS OF ANTITUBERCULOSIS AGENTS IN HIV INFECTED PTS WITH TB$124,146
M01 · FY2001 · RR
ACTG 329: NANDROLONE DECANOATE IN WOMEN WITH HIV WT LOS$124,146
M01 · FY2001 · RR
RS-79070 (VALGANCICLOVIR) VS IV GANCICLOVIR AS INDUCTION THERAPY FOR CMV RETINITI$124,146
M01 · FY2001 · RR
ACTG 341: MAC DISEASE IN ADVANCED HIV-1 INFECTION--HAART$124,146
M01 · FY2001 · RR
DNA PLASMID VACCINE IN ASYMPTOMATIC HIV$124,146
M01 · FY2001 · RR
ACTG 323--FLUCONAZOLE AS CHRONIC SUPPRESSIVE THERAPY VS EPISODIC THERAPY$124,146
M01 · FY2001 · RR
ACTG 368--INDINAVIR SULFATE, DMP266, &1592U89 IN HIV INFECTED SUBJECTS$124,146
M01 · FY2001 · RR
RS-79070 (VALGANCICLOVIR) VS IV GANCICLOVIR AS INDUCTION THERAPY FOR CMV RETINITI$0
M01 · FY2001 · RR
ACTG 323--FLUCONAZOLE AS CHRONIC SUPPRESSIVE THERAPY VS EPISODIC THERAPY$0
M01 · FY2001 · RR
ACTG 341: MAC DISEASE IN ADVANCED HIV-1 INFECTION--HAART$0
M01 · FY2001 · RR
ACTG 368--INDINAVIR SULFATE, DMP266, &1592U89 IN HIV INFECTED SUBJECTS$0
M01 · FY2001 · RR
ACTG 329: NANDROLONE DECANOATE IN WOMEN WITH HIV WT LOS$0
M01 · FY2001 · RR
DNA PLASMID VACCINE IN ASYMPTOMATIC HIV$0
M01 · FY2001 · RR
ACTG 309: PHARMACOKINETICS OF ANTITUBERCULOSIS AGENTS IN HIV INFECTED PTS WITH TB$0
M01 · FY2001 · RR
ACTG 888: IMPACT OF DISCONTINUING PRIMARY PCP PROPHYLAXIS IN CD4 COUNTS$0
M01 · FY2001 · RR
ACTG 393: SUBJECTS W/ DISSEMINATED MYCOBACTERIUM COMPLEX$0
M01 · FY2001 · RR
GENEVAX HIV, CANDIDATE DNA VACCINE SAFETY, TOLERABILITY AND IMMUNOGENEITY$0
M01 · FY2001 · RR
ACTG 362--EFFICACY OF AZITHROMYCIN PROPHYLAXIS FOR PREVENTION OF MAC DISEASES$0
M01 · FY2001 · RR
HUMAN CLINICAL STUDIES$0
P01 · FY2001 · AI
IMPACT OF HAART ON IMMUNE FUNCTIONS RELEVANT FOR MAC &OPPORTUNISTIC INFECTION$187,536
M01 · FY2000 · RR
ACTG 313--PHASE II TRIAL OF MEGESTROL ACETATE AND TESTOSTERONE$187,536
M01 · FY2000 · RR
ENTRY OF STAVUDINE INTO CEREBROSPINAL FLUID OF HIV INFECTED SUBJECTS$187,536
M01 · FY2000 · RR
ENTRY OF STAVUDINE INTO CEREBROSPINAL FLUID OF HIV INFECTED SUBJECTS$187,536
M01 · FY2000 · RR
ACTG266--STANDARD THERAPY VS STANDARD AND MSL 109 IN HIV+ PTS WITH CMV RETINITIS$187,536
M01 · FY2000 · RR
ACTG266--STANDARD THERAPY VS STANDARD AND MSL 109 IN HIV+ PTS WITH CMV RETINITIS$187,536
M01 · FY2000 · RR
IMPACT OF HAART ON IMMUNE FUNCTIONS RELEVANT FOR MAC &OPPORTUNISTIC INFECTION$187,536
M01 · FY2000 · RR
ACTG 313--PHASE II TRIAL OF MEGESTROL ACETATE AND TESTOSTERONE$187,536
M01 · FY2000 · RR
ACTG 336: NITAZOXANIDE FOR PERSONS W/ AIDS &CRYPTOSPORIDIOSIS$187,536
M01 · FY2000 · RR
ACTG 336: NITAZOXANIDE FOR PERSONS W/ AIDS &CRYPTOSPORIDIOSIS$187,536
M01 · FY2000 · RR
ACTG 888: IMPACT OF DISCONTINUING PRIMARY PCP PROPHYLAXIS IN CD4 COUNTS$25,137
M01 · FY2000 · RR
DNA PLASMID VACCINE IN ASYMPTOMATIC HIV$25,114
M01 · FY2000 · RR
ACTG266--STANDARD THERAPY VS STANDARD AND MSL 109 IN HIV+ PTS WITH CMV RETINITIS$25,114
M01 · FY2000 · RR
ACTG 323--FLUCONAZOLE AS CHRONIC SUPPRESSIVE THERAPY VS EPISODIC THERAPY$25,114
M01 · FY2000 · RR
ACTG 313--PHASE II TRIAL OF MEGESTROL ACETATE AND TESTOSTERONE$25,114
M01 · FY2000 · RR
ENTRY OF STAVUDINE INTO CEREBROSPINAL FLUID OF HIV INFECTED SUBJECTS$25,114
M01 · FY2000 · RR
ACTG 368--INDINAVIR SULFATE, DMP266, &1592U89 IN HIV INFECTED SUBJECTS$25,114
M01 · FY2000 · RR
ACTG 362--EFFICACY OF AZITHROMYCIN PROPHYLAXIS FOR PREVENTION OF MAC DISEASES$25,114
M01 · FY2000 · RR
GENEVAX HIV, CANDIDATE DNA VACCINE SAFETY, TOLERABILITY AND IMMUNOGENEITY$25,114
M01 · FY2000 · RR
IMPACT OF HAART ON IMMUNE FUNCTIONS RELEVANT FOR MAC &OPPORTUNISTIC INFECTION$25,114
M01 · FY2000 · RR
ACTG 336: NITAZOXANIDE FOR PERSONS W/ AIDS &CRYPTOSPORIDIOSIS$25,114
M01 · FY2000 · RR
ACTG 393: SUBJECTS W/ DISSEMINATED MYCOBACTERIUM COMPLEX$25,114
M01 · FY2000 · RR
RS-79070 (VALGANCICLOVIR) VS IV GANCICLOVIR AS INDUCTION THERAPY FOR CMV RETINITI$0
M01 · FY2000 · RR
RS-79070 (VALGANCICLOVIR) VS IV GANCICLOVIR AS INDUCTION THERAPY FOR CMV RETINITI$0
M01 · FY2000 · RR
RS-79070 (VALGANCICLOVIR) VS IV GANCICLOVIR AS INDUCTION THERAPY FOR CMV RETINITI$0
M01 · FY2000 · RR
ACTG 341: MAC DISEASE IN ADVANCED HIV-1 INFECTION--HAART$0
M01 · FY2000 · RR
ACTG 341: MAC DISEASE IN ADVANCED HIV-1 INFECTION--HAART$0
M01 · FY2000 · RR
ACTG 341: MAC DISEASE IN ADVANCED HIV-1 INFECTION--HAART$0
M01 · FY2000 · RR
ACTG 329: NANDROLONE DECANOATE IN WOMEN WITH HIV WT LOS$0
M01 · FY2000 · RR
ACTG 329: NANDROLONE DECANOATE IN WOMEN WITH HIV WT LOS$0
M01 · FY2000 · RR
ACTG 329: NANDROLONE DECANOATE IN WOMEN WITH HIV WT LOS$0
M01 · FY2000 · RR
ACTG 309: PHARMACOKINETICS OF ANTITUBERCULOSIS AGENTS IN HIV INFECTED PTS WITH TB$0
M01 · FY2000 · RR
ACTG 309: PHARMACOKINETICS OF ANTITUBERCULOSIS AGENTS IN HIV INFECTED PTS WITH TB$0
M01 · FY2000 · RR
ACTG 309: PHARMACOKINETICS OF ANTITUBERCULOSIS AGENTS IN HIV INFECTED PTS WITH TB$0
M01 · FY2000 · RR
ACTG 888: IMPACT OF DISCONTINUING PRIMARY PCP PROPHYLAXIS IN CD4 COUNTS$0
M01 · FY2000 · RR
ACTG 888: IMPACT OF DISCONTINUING PRIMARY PCP PROPHYLAXIS IN CD4 COUNTS$0
M01 · FY2000 · RR
ACTG 393: SUBJECTS W/ DISSEMINATED MYCOBACTERIUM COMPLEX$0
M01 · FY2000 · RR
ACTG 393: SUBJECTS W/ DISSEMINATED MYCOBACTERIUM COMPLEX$0
M01 · FY2000 · RR
GENEVAX HIV, CANDIDATE DNA VACCINE SAFETY, TOLERABILITY AND IMMUNOGENEITY$0
M01 · FY2000 · RR
GENEVAX HIV, CANDIDATE DNA VACCINE SAFETY, TOLERABILITY AND IMMUNOGENEITY$0
M01 · FY2000 · RR
ACTG 362--EFFICACY OF AZITHROMYCIN PROPHYLAXIS FOR PREVENTION OF MAC DISEASES$0
M01 · FY2000 · RR
ACTG 362--EFFICACY OF AZITHROMYCIN PROPHYLAXIS FOR PREVENTION OF MAC DISEASES$0
M01 · FY2000 · RR
ACTG 368--INDINAVIR SULFATE, DMP266, &1592U89 IN HIV INFECTED SUBJECTS$0
M01 · FY2000 · RR
ACTG 368--INDINAVIR SULFATE, DMP266, &1592U89 IN HIV INFECTED SUBJECTS$0
M01 · FY2000 · RR
ACTG 323--FLUCONAZOLE AS CHRONIC SUPPRESSIVE THERAPY VS EPISODIC THERAPY$0
M01 · FY2000 · RR
ACTG 323--FLUCONAZOLE AS CHRONIC SUPPRESSIVE THERAPY VS EPISODIC THERAPY$0
M01 · FY2000 · RR
DNA PLASMID VACCINE IN ASYMPTOMATIC HIV$0
M01 · FY2000 · RR
DNA PLASMID VACCINE IN ASYMPTOMATIC HIV$0
M01 · FY2000 · RR